- Home
- ACXP vs BIAF Comparison
ACXP vs BIAF Comparison
Compare ACXP & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- BIAF
- Stock Information
- Founded
- ACXP 2017
- BIAF 2014
- Country
- ACXP United States
- BIAF United States
- Employees
- ACXP N/A
- BIAF N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ACXP Health Care
- BIAF Health Care
- Exchange
- ACXP Nasdaq
- BIAF Nasdaq
- Market Cap
- ACXP 6.8M
- BIAF 7.6M
- IPO Year
- ACXP 2021
- BIAF 2022
- Fundamental
- Price
- ACXP $4.12
- BIAF $0.18
- Analyst Decision
- ACXP Strong Buy
- BIAF Hold
- Analyst Count
- ACXP 3
- BIAF 1
- Target Price
- ACXP $143.67
- BIAF N/A
- AVG Volume (30 Days)
- ACXP 67.3K
- BIAF 12.0M
- Earning Date
- ACXP 11-12-2025
- BIAF 11-13-2025
- Dividend Yield
- ACXP N/A
- BIAF N/A
- EPS Growth
- ACXP N/A
- BIAF N/A
- EPS
- ACXP N/A
- BIAF N/A
- Revenue
- ACXP N/A
- BIAF $7,681,059.00
- Revenue This Year
- ACXP N/A
- BIAF N/A
- Revenue Next Year
- ACXP N/A
- BIAF $20.04
- P/E Ratio
- ACXP N/A
- BIAF N/A
- Revenue Growth
- ACXP N/A
- BIAF 4.99
- 52 Week Low
- ACXP $3.80
- BIAF $0.16
- 52 Week High
- ACXP $44.00
- BIAF $2.26
- Technical
- Relative Strength Index (RSI)
- ACXP 36.61
- BIAF 36.96
- Support Level
- ACXP $4.09
- BIAF $0.24
- Resistance Level
- ACXP $4.34
- BIAF $0.45
- Average True Range (ATR)
- ACXP 0.45
- BIAF 0.03
- MACD
- ACXP 0.10
- BIAF 0.00
- Stochastic Oscillator
- ACXP 8.73
- BIAF 3.60
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.